Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Radiopharm Theranostics Limited ( (AU:RAD) ) is now available.
Radiopharm Theranostics Limited has notified the market of the issue of 99,294,000 unquoted options under its employee incentive scheme, which are not intended to be quoted on the ASX and have various expiry dates and exercise prices. The issuance of these unquoted equity securities is designed to support the company’s remuneration and retention strategy by aligning employee incentives with shareholder interests, potentially leading to future dilution if the options are exercised, but also signaling a focus on long-term value creation and staff engagement.
The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.06 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
More about Radiopharm Theranostics Limited
Average Trading Volume: 12,079,242
Technical Sentiment Signal: Buy
Current Market Cap: A$99.24M
For detailed information about RAD stock, go to TipRanks’ Stock Analysis page.